Opus Genetics is trading 5.8% up today at $3.26 as the stock rebounds from a recent pullback, largely tracking a surge in the broader biotechnology industry.
- The move appears driven by sector-wide momentum rather than company-specific news, as the SPDR S&P Biotech ETF (XBI) gained over 2%.
- Positive sentiment across the biotech space is being fueled by upbeat M&A activity and clinical trial headlines, providing a tailwind for the stock.